Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...

Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...

周二，Oppenheimer调整了对Sage Therapeutics (NASDAQ:SAGE)的展望，将目标价从之前的10美元下调至9美元，同时维持对该股的"表现"评级。这一调整是在Sage宣布其药物dalzanemdor未能在评估阿尔茨海默病相关轻度认知障碍（AD-MCI）患者治疗的2期LIGHTWAVE研究中达到主要目标之后做出的。 LIGHTWAVE研究的结果被视为一个挫折，尽管在该药物 ...

Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...